Clinical Trial Update: Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of continuous dosing with PF-00299804 in recurrent or metastatic head and neck squamous cell carcinoma has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• PF-00299804

Snippet

Sponsor: Pfizer | Conditions: Head and Neck Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2021-02-09